Literature DB >> 19359180

The complex dance of the molecular chaperone Hsp90.

Len Neckers1, Mehdi Mollapour, Shinji Tsutsumi.   

Abstract

Hsp90 chaperone function requires traversal of a nucleotide-dependent conformational cycle, but the slow and variable rate of Hsp90-mediated ATP hydrolysis is difficult to envision as a determinant of conformational change. A recent study solves this dilemma by showing that Hsp90 samples multiple conformational states in the absence of nucleotides, which serve to influence, but not direct, the cycle. The conformational program of Hsp90 is conserved from bacteria to humans, although the population dynamics are species specific.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359180      PMCID: PMC7282695          DOI: 10.1016/j.tibs.2009.01.006

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  23 in total

Review 1.  Heat shock protein 90 as a molecular target for cancer therapeutics.

Authors:  Jennifer S Isaacs; Wanping Xu; Len Neckers
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

2.  Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex.

Authors:  Maruf M U Ali; S Mark Roe; Cara K Vaughan; Phillipe Meyer; Barry Panaretou; Peter W Piper; Chrisostomos Prodromou; Laurence H Pearl
Journal:  Nature       Date:  2006-04-20       Impact factor: 49.962

3.  The ATPase cycle of the mitochondrial Hsp90 analog Trap1.

Authors:  Adriane Leskovar; Harald Wegele; Nicolas D Werbeck; Johannes Buchner; Jochen Reinstein
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

4.  The ATPase cycle of the endoplasmic chaperone Grp94.

Authors:  Stephan Frey; Adriane Leskovar; Jochen Reinstein; Johannes Buchner
Journal:  J Biol Chem       Date:  2007-10-09       Impact factor: 5.157

5.  An acetylation site in the middle domain of Hsp90 regulates chaperone function.

Authors:  Bradley T Scroggins; Kenneth Robzyk; Dongxia Wang; Monica G Marcu; Shinji Tsutsumi; Kristin Beebe; Robert J Cotter; Sara Felts; David Toft; Larry Karnitz; Neal Rosen; Len Neckers
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

Review 6.  Hsp90 inhibitors as novel cancer chemotherapeutic agents.

Authors:  Len Neckers
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

7.  Post-translational modification of heat-shock protein 90: impact on chaperone function.

Authors:  Bradley T Scroggins; Len Neckers
Journal:  Expert Opin Drug Discov       Date:  2007-10       Impact factor: 6.098

Review 8.  The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Authors:  M F Barginear; C Van Poznak; N Rosen; S Modi; C A Hudis; D R Budman
Journal:  Curr Cancer Drug Targets       Date:  2008-09       Impact factor: 3.428

9.  Apo-Hsp90 coexists in two open conformational states in solution.

Authors:  Patrick Bron; Emmanuel Giudice; Jean-Paul Rolland; Rubén M Buey; Pascale Barbier; J Fernando Díaz; Vincent Peyrot; Daniel Thomas; Cyrille Garnier
Journal:  Biol Cell       Date:  2008-07       Impact factor: 4.458

10.  Conserved conformational changes in the ATPase cycle of human Hsp90.

Authors:  Klaus Richter; Joanna Soroka; Lukasz Skalniak; Adriane Leskovar; Martin Hessling; Jochen Reinstein; Johannes Buchner
Journal:  J Biol Chem       Date:  2008-04-09       Impact factor: 5.157

View more
  14 in total

Review 1.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

2.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors.

Authors:  Mahmoud A Al-Sha'er; Mutasem O Taha
Journal:  J Mol Model       Date:  2012-06-16       Impact factor: 1.810

4.  Mutation of essential Hsp90 co-chaperones SGT1 or CNS1 renders yeast hypersensitive to overexpression of other co-chaperones.

Authors:  Jill L Johnson; Abbey D Zuehlke; Victoria R Tenge; Jordan C Langworthy
Journal:  Curr Genet       Date:  2014-06-13       Impact factor: 3.886

5.  HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.

Authors:  Takuya Osada; Erika J Crosby; Kensuke Kaneko; Joshua C Snyder; Joshua D Ginzel; Chaitanya R Acharya; Xiao-Yi Yang; Thomas J Polascik; Ivan Spasojevic; Rendon C Nelson; Amy Hobeika; Zachary C Hartman; Leonard M Neckers; Andre Rogatko; Philip F Hughes; Jiaoti Huang; Michael A Morse; Timothy Haystead; H Kim Lyerly
Journal:  Mol Cancer Ther       Date:  2021-10-21       Impact factor: 6.261

Review 6.  Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.

Authors:  Annerleim Walton-Diaz; Sahar Khan; Dimitra Bourboulia; Jane B Trepel; Len Neckers; Mehdi Mollapour
Journal:  Future Med Chem       Date:  2013-06       Impact factor: 3.808

7.  Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Authors:  Jared J Barrott; Philip F Hughes; Takuya Osada; Xiao-Yi Yang; Zachary C Hartman; David R Loiselle; Neil L Spector; Len Neckers; Narasimhan Rajaram; Fangyao Hu; Nimmi Ramanujam; Ganesan Vaidyanathan; Michael R Zalutsky; H Kim Lyerly; Timothy A Haystead
Journal:  Chem Biol       Date:  2013-09-12

8.  Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.

Authors:  Aarif Ahsan; Susmita G Ramanand; Ingrid L Bergin; Lilli Zhao; Christopher E Whitehead; Alnawaz Rehemtulla; Dipankar Ray; William B Pratt; Theodore S Lawrence; Mukesh K Nyati
Journal:  Neoplasia       Date:  2014-02       Impact factor: 5.715

9.  Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.

Authors:  Aarif Ahsan; Susmita G Ramanand; Christopher Whitehead; Susan M Hiniker; Alnawaz Rehemtulla; William B Pratt; Shruti Jolly; Christopher Gouveia; Kristy Truong; Carter Van Waes; Dipankar Ray; Theodore S Lawrence; Mukesh K Nyati
Journal:  Neoplasia       Date:  2012-08       Impact factor: 5.715

10.  Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulations.

Authors:  Giulia Morra; Raffaello Potestio; Cristian Micheletti; Giorgio Colombo
Journal:  PLoS Comput Biol       Date:  2012-03-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.